ClariVest Asset Management’s Corcept Therapeutics CORT Stock Holding History

ClariVest Asset Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-61,649	Closed	-$969K	–	732
2018 Q2	$969K	Sell	61,649 -2,321	-4%	-$40.4K	0.02%	448
2018 Q1	$1.05M	Sell	63,970 -91,300	-59%	-$1.69M	0.02%	423
2017 Q4	$2.8M	Buy	155,270 +87,349	+129%	+$1.58M	0.05%	286
2017 Q3	$1.31M	Buy	+67,921	New	+$1.01M	0.03%	323

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ClariVest Asset Management's CORT Position: Q3 2018 in Review

ClariVest Asset Management sold out of Corcept Therapeutics (CORT) in Q3 2018, closing a stake of 61,649 shares — an estimated $969K sold.

ClariVest Asset Management first reported a position in CORT in Q3 2017 and held it in 4 quarters. The position peaked at $2.8M in Q4 2017. 207 funds tracked by Wall St. Rank hold CORT as of Q3 2018.

ClariVest Asset Management reported no remaining Corcept Therapeutics position as of Q3 2018 after selling out during the quarter.
ClariVest Asset Management sold 61,649 Corcept Therapeutics shares in Q3 2018, an estimated $969K.
ClariVest Asset Management first reported a position in Corcept Therapeutics in Q3 2017 and held it in 4 quarters.
ClariVest Asset Management's Corcept Therapeutics position peaked at $2.8M in Q4 2017.
207 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2018.

Based on ClariVest Asset Management's 13F filing for Q3 2018, filed 7 Nov 2018.